FDA Clearance Tracker · K223597
23andMe® Personal Genome Service® (PGS®) Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants)
Last checked: Nov 20, 2026Latest source record: Aug 31, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Aug 31, 2023
Substantially Equivalent
Time to decision
272 days
Received Dec 2, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K223597
- Device name
- 23andMe® Personal Genome Service® (PGS®) Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants)
- Applicant
- 23AndMe, Inc.
- Applicant location
- San Franciso, CA
- Received
- Dec 2, 2022
- Decided
- Aug 31, 2023
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.6090
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QAZ. The earliest in FDA's data is DEN170046, decided Mar 6, 2018.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K223597
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for 23AndMe, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K221885 · Decided Oct 26, 2022 · 119 days after receipt
Device type: Direct-To-Consumer Access Pharmacogenetic Assessment System (QDJ) · Laboratory Medicine & Pathology
K211499 · Decided Jan 6, 2022 · 237 days after receipt
Device type: Cancer Predisposition Risk Assessment System (QAZ) · Laboratory Medicine & Pathology
K193492 · Decided Aug 17, 2020 · 244 days after receipt
Device type: Direct-To-Consumer Access Pharmacogenetic Assessment System (QDJ) · Laboratory Medicine & Pathology
4 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.